CancerDrs

Brain Cancer clinical trials in Florida

53 actively recruiting brain cancer trials at 23 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Florida:
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Mount Sinai Medical Center — Miami Beach, Florida
  • Moffitt Cancer Center — Tampa, Florida
  • Cleveland Clinic-Weston — Weston, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Florida:
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Nicklaus Children's Hospital — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Florida:
  • Boca Raton Regional Hospital — Boca Raton, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Florida:
  • Mayo Clinic Jacksonville — Jacksonville, Florida
  • Miami Cancer Institute — Miami, Florida
  • St Joseph's Children's Hospital of Tampa — Tampa, Florida
  • Moffitt Cancer Center — Tampa, Florida
  • Cleveland Clinic Florida — Weston, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Florida:
  • University of Florida Health — Gainesville, Florida
  • Mayo Clinic - Florida — Jacksonville, Florida
  • University of Miami Health — Miami, Florida
  • Orlando Health Cancer Institute — Orlando, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …

Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Florida:
  • Mayo Clinic Cancer Center — Jacksonville, Florida
  • Sylvester Comprehensive Cancer Center* — Miami, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Florida:
  • UF Health Neuromedicine — Gainesville, Florida
  • Mayo Clinic - Florida — Jacksonville, Florida
  • Miami Cancer Institute — Miami, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…

Sponsor: CarThera
NCT ID: NCT05902169
Sites in Florida:
  • Mayo Clinic of Jacksonville Florida — Jacksonville, Florida
  • Miami Cancer Institute — Miami, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…

Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Florida:
  • Advent Health — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec
NCT ID: NCT05317858
Sites in Florida:
  • Broward Health — Fort Lauderdale, Florida
  • Miami Cancer Institute at Baptist Health — Miami, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…

Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Florida:
  • Mayo Clinic in Florida — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Florida:
  • Johns Hopkins All Children's Hospital — St. Petersburg, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Florida:
  • Local Institution - 2105 — Orlando, Florida
  • Local Institution - 2120 — Orlando, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Florida:
  • Mayo Clinic_Jacksonville — Jacksonville, Florida
  • Baptist Health Miami Cancer Institute — Miami, Florida
  • Tampa General Hospital — Tampa, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in Florida:
  • Baptist MD Anderson Cancer Center — Jacksonville, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Florida:
  • Mayo Clinic Jacksonville — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Florida:
  • Nicklaus Children's Hospital — Miami, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05188508
Sites in Florida:
  • BAPTIST ALLIANCE - MCI (Data Collection Only) — Miami, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…

Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Florida:
  • MDR Core Network — Boynton Beach, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pa…

Sponsor: Eikon Therapeutics
NCT ID: NCT06907043
Sites in Florida:
  • Florida Cancer Center — Lake Mary, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Florida:
  • Moffitt — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…

Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Florida:
  • Mayo Clinic Hospital — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide …

Sponsor: Mayo Clinic
NCT ID: NCT07708961
Sites in Florida:
  • Mayo Clinic in Florida — Jacksonville, Florida
View on ClinicalTrials.gov →

Showing 25 of 53 trials with sites in Florida. See all brain cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19